Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ALERT**FDA approval for Onko Sure has lapsed.**ALERT
In order to manufacture and sell Onko Sure, Radient is required to pay a yearly registration fee to the FDA. They have not paid the 2013 fee and the approval has now lapsed preventing them from legally manufacturing and selling Onko Sure.
Establishment
Name6
7 Registration Number Current
Registration Yr
AMDL Diagnostics, INC.8 CA/USA
2030936 2012
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm
Enter DR-70 under Proprietary
Name and click on quick search.
Radient has not made any updates to their website for over a year.
However, GenWay has and they have recently eliminated Onko Sure from their website.
There is another license fee to be paid to the state of California.
Radient probably does not have a current license from California either.
http://www.cdph.ca.gov/pubsforms/forms/CtrldForms/cdph8679.pdf
You seem to be overly excited about $380 in total sales this morning. If anything, this shows a huge lack of interest in the stock.
Don't you think that if Onko Sure was worth anything at all, wouldn't Radient have found some way to maintain the FDA approval of their product?
If anything al all is being demonstrated this morning is that the stock if worthless. Radient cannot even legally manufacture and sell test kits anymore.
A statement from Radient's 10K:
"Obtaining regulatory approval in the U.S. for our Onko-Sure® test kit was costly, and it remains costly to maintain."
The fees to maintain regulatory approval are probably more than Radient can afford to pay.
http://www.radient-pharma.com/pdf/RadientPharma_10k%20123110.pdf
Heavyweight, the FDA website states that Radient has NOT paid the registration fee to market Onko Sure for 2013. You cannot get more current information that that.
That would also explain why Onko Sure was recently removed from the GenWay website. It is not legal to sell it any more.
Attempting to patent something has NOTHING to do with marketing the product.
Onko Sure has NEVER been used in combination with ANYTHING.
Jimtash, how do you propose to explain all those unresolved trades that are being reported on a daily basis?
Jimtash, you obviously do not know the difference between ELISA and CLIA.
Enzyme-linked immuno sorbent assay (ELISA) is a test that uses antibodies and color change to identify a substance.
The CLIA Program sets standards and issues certificates for clinical laboratory testing.[2] CLIA defines a clinical laboratory as any facility which performs laboratory testing on specimens derived from humans.
All of the Onko Sure test kits to be marketed in the USA, Canada and elsewhere ware all manufactured to use ELISA test machines.
It is now illegal to sell the test kits in the USA and Canada.
Radient is requird to pay a yearly registration fee to maintain the FDA approval of Onko Sure. They have not paid the fee for 2013 so it is now illegal for anyone to sell Onko Sure in the USA or Canada.
Radient has not paid the 2013 FDA medical device registration fees. The product can no longer be sold in the USA and Canada.
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm
FDA medical device registration for Onko Sure has expired.
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm
This was the conference call where MacLellan agreed that Onko Sure should not be used as a general screen for cancer.
http://www.radient-pharma.com/news/pdf/2010/062210%20June%20investor%20call.pdf
Jimtash, Jade Pharmceuticals manufactured a cosmetic product. When Jade was written off as a subsidiary, there was no longer any connection brtween radient and cosmetics.
http://www.radient-pharma.com/company/about_jade.html
ALERT**All patents have now been seized.**ALERT
The other patent and patent application previously indicated a "security interest" for Camofi Master. Now both of them show they are totally assigned to Camofi Master. The latest patent application on the peptide has also been seized.
Peptide patent application has been seized by Smithline as of March 15, 2013.
http://assignments.uspto.gov/assignments/q?db=pat&pub=20120270238
Total Assignments: 3
Patent #:
NONE
Issue Dt:
Application #:
13502306
Filing Dt:
04/16/2012
Publication #:
20120270238
Pub Dt:
10/25/2012
Inventors:
Ricardo J. Moro, Ralph H. Schmid
Title:
Peptides That Bind the Alpha-Fetoprotein (AFP) Receptor and Uses Thereof
Assignment: 1
Reel/Frame:
030031/0874
Recorded: 03/18/2013
Pages: 22
Conveyance:
ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).
Assignor:
MORO, RICARDO, DR.
Exec Dt:
10/01/2009
Assignee:
WHISPERING OAKS INTERNATIONAL, INC.
7080 RIVER ROAD, SUITE 215
RICHMOND, BRITISH COLUMBIA, CANADA V6X 1X5
Correspondent:
MILTON SPRINGUT
75 ROCKFELLER PLAZA, 19FL
NEW YORK, NY 10019
Assignment: 2
Reel/Frame:
030034/0160
Recorded: 03/18/2013
Pages: 2
Conveyance:
CHANGE OF NAME (SEE DOCUMENT FOR DETAILS).
Assignor:
WHISPERING OAKS INTERNATIONAL, INC.
Exec Dt:
10/27/2009
Assignee:
BIOCUREX, INC
7080 RIVER ROAD, SUITE 215
RICHMOND, BRITISH COLUMBIA, CANADA V6X 1X5
Correspondent:
MILTON SPRINGUT LAW PC
75 ROCKFELLER PLAZA, 19FL
NEW YORK, NY 10019
Assignment: 3
Reel/Frame:
030038/0042
Recorded: 03/19/2013
Pages: 4
Conveyance:
ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).
Assignor:
BIOCUREX, INC.
Exec Dt:
03/15/2013
Assignees:
CAMOFI MASTER LDC
C/O CENTER COURT ASSET MANAGEMENT, LLC
11 EAST 44TH STREET, SUITE 1600
NEW YORK, NEW YORK 10017
CAMHZN MASTER LDC
C/O CENTER COURT ASSET MANAGEMENT, LLC
11 EAST 44TH STREET, SUITE 1600
NEW YORK, NEW YORK 10017
Correspondent:
SPRINGUT LAW PC
75 ROCKFELLER PLAZA, 19FL
NEW YORK, NY 10019
People are confused when they think this product has some value. They do not understand the basics of sensitivity and specificity when applided to Onko Sure when used for screening.
I read one post years ago by a doctor who termed this type of test to be a "WASTE OF TIME". Years ago, back in the 1980's, there were multiple articles praising a universal cancer marker's value in detecting cancer. However, none of the universal markers ever discovered, including Onko sure, ever had a high enough specificity to be of any clinical use for screening.
The hard cold fact about Onko Sure is that when the test is given to those over 50 years old, there would be over 50 false positives for every actual case of cancer discovered.
That is TOTALLY UNACCEPTABLE.
The impact on those people who would be incorrectly told they have cancer and the number of tests they would have to undergo and still never prove they don't have cancer? It would be devastating to those people and who would pay for all this unnecessary additional testing?
Do you now understand why the Indian government never bought into the screening program hyped by Radient? During a conference call, I presented those facts to MacLellan and he indeed responded that my facts were correct and Onko Sure should not be used as a general screen.
Monitoring in the only proper use for Onko Sure and it doesn't do a very good job of that.
Scrupie, Richard Smithline who runs the two hedge funds who are in the process of foreclosing are taking all of the assets. They are taking the patents, the lab equipment, and the shell.
The longer they wait, the shell decreases in value for resale so you can expect things to happen fairly quickly.
Moro will make no more SEC filings. There will be no 10K filed this year. It is due in 7 more days. Moro has also not filed any 8K for the recent material events. Nothing on the lab closing, nothing about shutting down the websites and nothing on the default nor foreclosure proceedings.
Yes, lots of people lost money in this stock including me.
The lenders were busy today selling over 37 million shares. Buyers at .0003 certainly makes for happy lenders.
No volume today so maybe the previous buyers have finally figured out the oompany has shut down operations.
It takes money to do an IPO and besides, FSU cancelled the agreement with NuVax.
The biggst key you need to look at is that nothing has changed about Radient since the lenders began converting and selling shares but that the debt continues to grow and the share count marches toward the 5 billion authorized.
BTW, it dis surprise me that one of the lenders did not hit the bid at .0002 before close.
Keep in mind that I did in fact project that the lenders would max out the authorized shares sometimein February or March. The daily volume has dropped some since I made that projection but I don't think it is that far off.
Remember, the lenders have 45 days before they have to cover any unresolved trades.
Dcspka, since I made the earlier post, some larger trades at .0003 have been made.
It might stick depending upon what the lenders do. It is really unknown what will happen with the stock when the lneders finally max out the 5 million authorized shares.
It may go up some more or the volume may just dry up with no sales and the volume dries up.
Stockstuffer, that report is the daily unresolved trade data. If you want to see the actual short data, you the link I posted.
The unresolved trades originate from the lender having their broker sell shares that have not yet been converted. That comes under a different SEC rule and those sales actually have 45 days to cover and those sales can even continue if the company goes on the SHO list.
What the unresolved trade report best shows is an indication of how many shares the lenders are selling.
Stockstuffer stated: " shorts have to cover."
There are no shorts in this stock. You're dreaming.
http://www.otcmarkets.com/stock/RXPC/short-sales+
I wold not even call those buying this stock "investors". They are gamblers. Nothing else.
The buys today at .0003 are small and just made by those attempting to push the share price up.
Jimtash, for the O/S count to go down, there is just one way it happens. Shares have to be turned back in to the TA to be cancelled.
Do you remember a post where I stated the process of taking losses for tax purposes. As a service, brokers will in fact "buy" worthless stock from investors to allow those investors to take losses for tax purposes. The brokers then send the shares back to the TA for "disposal".
Unfortunately, it just allows the lenders to get more shares and they go right back into circulation again.
Thanks antisense, this stock taught me a lot also.
A lot of good people got taken advantage of because they believed the "good doctor" was not capable of the bad deeds he has done.
Moro made lots of threats directored toward me, he threatened to sue, told others they should sue me and posted many times on the board in at attempt to suppress the truth.
The sad part, IMO, is also the fact that he was able to line his pockets with SR&ED money before he shut things down.
Not only is B&L going to buy out the royalty stream for the quinalone, they are an excellent candidate to license BromSite in additon to purchasing the company at some point.
At this time, I would put a buy rec on the stock. When the fund, Coliseum Capital Management, LLC, has completed their selling program, the stock will be free to gain value.
A fund who held more than 14.7 million shares last year has been consistently selling for many months and has greatly impacted the price of the stock. This year, they held less than 5% so no form 13G was filed. It will certainly help the share price when their selling program is completed.
Recent conference call indicates Insite is going to sell the royalty stream from their Quinalone licensed and marketed by B&L in order to raise additional cash rather than more dilution. I see that as a positive move.
I think the bad days are over and the future is looking much better for Insite Vision.
Positive Phase 3 Results for BromSite™ announced
http://phx.corporate-ir.net/phoenix.zhtml?c=86061&p=irol-newsArticle&ID=1797497&highlight=
The backlog on patent re-examinations is HUGE. The article stating that the wait could take YEARS was published on Feb 14, 2013.
ALERT*** BioCurex shuts down lab and websites***ALERT
The lender is in the process of foreclosing on all assets of BioCurex. BioCurex has defaulted on a loan to Camofi Master as of January 2013 and the loan gave them a lien on ALL assets of BioCurex.
Call (604) 207 5190. or toll free at (866) 884 8669 to hear the taped message.
All websites have been shut down. Looks like that is why the taped phone message gives the yahoo address for contact.
http://www.biocurex.com
There was a low percentage of unresolved trades today. That is why the price stayed at .0002 until after hours.
The $.0001's came after hours and huge
$0.0001
9,060,000
OTO
16:12:24
Jimtash, please explain why ANYONE would be waiting on a patent application for a rehash of DR-70.
Besides, that application has a huge issue with Junda for prior patent.
Jimtash, if you still plan on pinning all hopes on a patent issue, you should look to purchase a really comfy chair.
There is no one waiting on a patent so it really wont make any difference anyway but I thought I would post some reality to you patent hopes.